Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPMY Astellas Pharma	$9.66 -2.1%	$9.52	$8.37 ▼ $13.14	$17.48B	0.27	201,130 shs	181,290 shs
OPHLF Ono Pharmaceutical	$10.38	$11.09	$9.20 ▼ $16.05	$4.87B	0.6	8,600 shs	2 shs
RPRX Royalty Pharma	$33.75 +0.9%	$32.47	$24.05 ▼ $34.32	$18.98B	0.49	3.52 million shs	2.65 million shs
TEVA Teva Pharmaceutical Industries	$17.24 -1.6%	$15.67	$12.47 ▼ $22.80	$19.54B	0.62	10.09 million shs	10.91 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPMY Astellas Pharma	-2.13%	-0.41%	-4.26%	-2.03%	-5.57%
OPHLF Ono Pharmaceutical	0.00%	0.00%	-18.60%	-7.30%	-27.07%
RPRX Royalty Pharma	+0.93%	+3.40%	+5.11%	+2.24%	+25.00%
TEVA Teva Pharmaceutical Industries	-1.85%	-1.98%	+6.83%	+12.34%	+2.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPMY Astellas Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	4.6677 of 5 stars	3.6	1.0	3.3	3.7	2.9	1.7	1.9
TEVA Teva Pharmaceutical Industries	2.9138 of 5 stars	3.6	3.0	0.8	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPMY Astellas Pharma	0.00	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	0.00	N/A	N/A	N/A
RPRX Royalty Pharma	3.25	Buy	$47.33	40.25% Upside
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.50	42.15% Upside

Current Analyst Ratings Breakdown

Latest OPHLF, TEVA, RPRX, and ALPMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/16/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$51.00
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
4/28/2025	TEVA Teva Pharmaceutical Industries	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/28/2025	RPRX Royalty Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/6/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $20.00

(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPMY Astellas Pharma	$11.11B	1.57	$1.15 per share	8.42	$5.84 per share	1.65
OPHLF Ono Pharmaceutical	$3.48B	1.40	$1.97 per share	5.28	$11.54 per share	0.90
RPRX Royalty Pharma	$2.26B	8.38	$4.25 per share	7.94	$17.94 per share	1.88
TEVA Teva Pharmaceutical Industries	$16.62B	1.18	$3.41 per share	5.05	$4.75 per share	3.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPMY Astellas Pharma	$113M	$0.17	N/A	14.21	N/A	-3.10%	13.69%	6.06%	7/29/2025 (Estimated)
OPHLF Ono Pharmaceutical	$883.05M	$0.70	9.98	∞	N/A	15.15%	9.10%	7.12%	7/28/2025 (Estimated)
RPRX Royalty Pharma	$858.98M	$1.85	23.28	6.94	2.31	37.94%	24.40%	14.01%	8/14/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.55	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)

Latest OPHLF, TEVA, RPRX, and ALPMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	RPRX Royalty Pharma	$0.99	$1.06	+$0.07	$0.41	$724.69 million	$839.00 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
4/25/2025	Q4 2025	ALPMY Astellas Pharma	$0.1474	$0.27	+$0.1226	$0.27	$3.02 billion	$3.22 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPMY Astellas Pharma	$0.33	3.42%	N/A	194.12%	N/A
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.61%	+7.30%	47.57%	5 Years
TEVA Teva Pharmaceutical Industries	$1.01	5.87%	N/A	N/A	N/A

Latest OPHLF, TEVA, RPRX, and ALPMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/21/2025	RPRX Royalty Pharma	quarterly	$0.22	2.7%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPMY Astellas Pharma	0.39	1.04	0.80
OPHLF Ono Pharmaceutical	0.14	3.55	2.80
RPRX Royalty Pharma	0.64	1.44	1.44
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPMY Astellas Pharma	N/A
OPHLF Ono Pharmaceutical	N/A
RPRX Royalty Pharma	54.35%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ALPMY Astellas Pharma	N/A
OPHLF Ono Pharmaceutical	N/A
RPRX Royalty Pharma	18.90%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPMY Astellas Pharma	14,754	1.81 billion	N/A	Not Optionable
OPHLF Ono Pharmaceutical	3,853	469.71 million	N/A	Not Optionable
RPRX Royalty Pharma	80	562.24 million	477.83 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

OPHLF, TEVA, RPRX, and ALPMY Headlines

Recent News About These Companies

Matthew Shields Sells 6,206 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

June 5 at 6:03 PM | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

June 5 at 7:09 AM | seekingalpha.com

Teva Pharmaceutical prices and manages debt

June 4 at 7:31 AM | msn.com

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

June 3 at 5:30 PM | globenewswire.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Update

June 3 at 3:08 PM | marketbeat.com

Teva Pharmaceutical Industries Ltd. Announces Early Tender Results and Increased Tender Caps for Note Offers

June 3 at 7:37 AM | quiverquant.com

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

June 3 at 7:16 AM | globenewswire.com

Bourgeon Capital Management LLC Has $5.54 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 3 at 6:18 AM | marketbeat.com

Zacks Research Analysts Cut Earnings Estimates for TEVA

June 3 at 1:17 AM | americanbankingnews.com

Zacks Research Has Bearish Forecast for TEVA Q3 Earnings

June 2, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd: New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

June 1, 2025 | finanznachrichten.de

15,048 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Jefferies Financial Group Inc.

June 1, 2025 | marketbeat.com

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care ...

May 31, 2025 | gurufocus.com

Teva Pharmaceutical Industries Limited (TEVA) Highlights Long-Acting Injectable Advancements for Schizophrenia at 2025 Psych Congress

May 31, 2025 | insidermonkey.com

Zacks Research Issues Positive Outlook for TEVA Earnings

May 31, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Centaurus Financial Inc.

May 31, 2025 | marketbeat.com

Siemens Fonds Invest GmbH Invests $611,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 31, 2025 | marketbeat.com

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

May 30, 2025 | globenewswire.com

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

May 30, 2025 | globenewswire.com

Teva Gets High Court Extension to Challenge Orange Book Ruling

May 30, 2025 | news.bloomberglaw.com

Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 4% - Should You Sell?

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPHLF, TEVA, RPRX, and ALPMY Company Descriptions

Astellas Pharma OTCMKTS:ALPMY

$9.66 -0.21 (-2.13%)

As of 06/5/2025 03:59 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Ono Pharmaceutical OTCMKTS:OPHLF

$10.38 0.00 (0.00%)

As of 06/3/2025

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Royalty Pharma NASDAQ:RPRX

$33.75 +0.31 (+0.93%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$33.34 -0.41 (-1.23%)

As of 08:54 AM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Teva Pharmaceutical Industries NYSE:TEVA

$17.24 -0.29 (-1.63%)

Closing price 06/5/2025 03:59 PM Eastern

Extended Trading

$17.55 +0.31 (+1.80%)

As of 09:00 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time